Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…

Great 1. Day #urotrials meeting - kudos to Marc-Oliver Grimm for setting this up 👋 OncoAlert Advanced Prostate Cancer Consensus Conference Tom Powles

Great to have Tom Powles at #UroTrials in Düsseldorf. Prediction: 80% less cystectomies in the next five years given recent advances in the field. So rCx only in case of local complications/bleeding in the future? Axel S. Merseburger jim catto Benjamin J. Davies MD Alexander Kutikov MD

Change in Total Lesion PSMA (TLP) predicts survival in pts with mCRPC treated with Lu-PSMA therapy lnkd.in/d8aCa4MH Samer Ezziddin

CHMP gives a positive recommendation for Enfortumab Vedotin and Pembrolizumab in 1st line advanced UC. Paving the way for use in Europe. merck.com/news/merck-rec…

Happy to share this team effort - first presented ⁦ASCO 24⁩ by Wolfgang Fendler. Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer ⁦Ken Herrmann⁩ ⁦Uniklinikum Essen⁩ sciencedirect.com/science/articl…

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

🚨 Morgen startet der Deutsche Urologenkongress in Leipzig! 🩺 Freut euch auf spannende Vorträge, neueste Forschungsergebnisse und den Austausch mit Kolleg:innen aus der Urologie. #DGU24 #Urologie #Leipzig Christian Wülfing DGU DGU Kongress GeSRU GeSRU Academics BvDUrologie

🚨4-year follow-up of the Gothenburg MRI-targeted only vs systematic biopsy for 🚨 NEJM >13k patients studied Biopsies of only MRI lesions leads to... 📉<Half as many biopsies (588➡️254) 📉<Half as many diagnoses of GG1 PCa (159➡️68) ⚖️No difference in ≥GG2 PCa (139 vs 117)

Prior #ARANOTE #ESMO24 data Simon C Marc-Oliver Grimm ESMO - Eur. Oncology OncoAlert European Association of Urology (EAU) silke gillessen Advanced Prostate Cancer Consensus Conference Neeraj Agarwal, MD, FASCO Yüksel Ürün Dra. María Natalia Gandur Quiroga Daniel Castellano DGU European Association of Urology (EAU) Declan Murphy

Begehbare Riesenprostata am Universitätsspital Zürich #USZ vom 04.-05. November 2024. Erleben Sie die #Prostata im #Movember hautnah. usz.ch/veranstaltung/…

Honored to present #AVENGER study results #EMUC24 - full story just submitted for publication European Urology Advances in Therapy European Association of Urology (EAU) Universitätsklinikum Schleswig-Holstein Carsten Ohlmann

Positive PFS results for the AKT inhibitor capivasertib in hormone sensitive PTEN defficent prostate cancer (with Abi and ADT). A trend towards OS (immature) described. Chemotherapy triplets are also used in high volume disease. astrazeneca.com/media-centre/p…

Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade Cancer Cell OncoAlert Tom Powles Petros Grivas

Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. pfizer.com/news/press-rel…

Big news! The European Medicines Agency’s Committee for Medicinal Products for Human Use approved Belzutifan for advanced kidney cancer and VHL disease: actionkidneycancer.org/belzutifan-app… #KidneyCancer Action Kidney Cancer

solution-akademie-veranstaltungen.de/auo-studiensym…

CHMP recommends durvalumab for EU approval as the first perioperative immunotherapy for MIBC. ASCO ESMO - Eur. Oncology European Association of Urology (EAU) OncoAlert Oncology Brothers Uromigos Syed A Hussain jim catto astrazeneca.com/media-centre/p…

Niraparib plus Abi delays rPFS in HRR+ particularly BRCA2m mHSPC in AMPLITUDE! #ASCO25 #MedIQASCO25 HR 0.63 is clinically meaningful.

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…